alternatives to glp-1 Top 5 Natural You Might Consider Natural Ozempic Alternatives: A Full

Description

Rising prevalence of diabetes and obesity, advancement in drug delivery technologies, and growing focus on preventive healthcare and personalized medicine are major key factors driving the market revenue growth of the GLP-1 Receptor Agonist market

Do not read the syringe at an angle

Giugliano D, Longo M, Caruso P, Maiorino MI, Bellastella G, Esposito K

In 2025, Novo Nordisks semaglutide awaits several first-time FDA decisions: 3Q 2025 the first GLP-1 (Wegovy) for metabolic dysfunction-associated steatohepatitis (MASH) 4Q 2025 the first oral GLP-1 ( oral formulation of Wegovy 25 mg ) for weight loss and weight loss plus secondary CV risk reduction 4Q 2025 Wegovy for heart failure with preserved ejection fraction and obesity October 2025 new indication for oral Rybelsus for secondary CV risk reduction 2025 Ozempic for T2DM and peripheral artery disease (PAD) Given the considerable continued growth expected in the GLP-1 pipeline, Prime Therapeutics (Prime) talented team of clinical experts actively monitors this emerging landscape